Cargando…

Pooled Safety Analysis of Baricitinib in Adult Participants with Atopic Dermatitis in the Japanese Subpopulation from Six Randomized Clinical Trials

INTRODUCTION: Baricitinib is an oral selective Janus kinase (JAK)1/JAK2 inhibitor approved in Japan and the European Union for the treatment of atopic dermatitis (AD). The aim of this study is to report pooled safety data for baricitinib in the Japanese subpopulation of the clinical development prog...

Descripción completa

Detalles Bibliográficos
Autores principales:	Katoh, Norito, Takita, Yasushi, Isaka, Yoshitaka, Nishikawa, Atsushi, Torisu-Itakura, Hitoe, Saeki, Hidehisa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9579605/ https://www.ncbi.nlm.nih.gov/pubmed/36255569 http://dx.doi.org/10.1007/s13555-022-00828-5

Ejemplares similares

Pooled Analysis of Baricitinib Tolerability in Patients With Atopic Dermatitis in Relation to Acne, Headache, and Gastrointestinal Events From 8 Clinical Trials
por: Wollenberg, Andreas, et al.
Publicado: (2023)

Atopic dermatitis disease registry in Japanese adult patients with moderate to severe atopic dermatitis (ADDRESS‐J): Baseline characteristics, treatment history and disease burden
por: Katoh, Norito, et al.
Publicado: (2019)

Baricitinib: A Review in Moderate to Severe Atopic Dermatitis
por: Hoy, Sheridan M.
Publicado: (2022)

The Roles of Sex Hormones in the Course of Atopic Dermatitis
por: Kanda, Naoko, et al.
Publicado: (2019)

Evaluation of standard treatments for managing adult Japanese patients with inadequately controlled moderate‐to‐severe atopic dermatitis: Two‐year data from the ADDRESS‐J disease registry
por: Katoh, Norito, et al.
Publicado: (2022)

Atopic Dermatitis: Identification and Management of Complicating Factors
por: Tamagawa-Mineoka, Risa, et al.
Publicado: (2020)

Treatment of Atopic Dermatitis with Baricitinib: First Real-life Experience
por: ROGNER, Danielle, et al.
Publicado: (2022)

Correction to: Baricitinib: A Review in Moderate to Severe Atopic Dermatitis
por: Hoy, Sheridan M.
Publicado: (2022)

Efficacy and safety of ixekizumab treatment in Japanese patients with moderate‐to‐severe plaque psoriasis: Subgroup analysis of a placebo‐controlled, phase 3 study (UNCOVER‐1)
por: Imafuku, Shinichi, et al.
Publicado: (2017)

Safety and Efficacy of Upadacitinib for Atopic Dermatitis in Japan: 2-Year Interim Results from the Phase 3 Rising Up Study
por: Katoh, Norito, et al.
Publicado: (2022)

Efficacy and safety of baricitinib in Japanese patients with autoinflammatory type I interferonopathies (NNS/CANDLE, SAVI, And AGS)
por: Kanazawa, Nobuo, et al.
Publicado: (2023)

Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis: Focus on Abrocitinib, Baricitinib, and Upadacitinib
por: Nogueira, Miguel, et al.
Publicado: (2021)

Baricitinib Lipid-Based Nanosystems as a Topical Alternative for Atopic Dermatitis Treatment
por: Garrós, Núria, et al.
Publicado: (2023)

Difamilast Ointment in Japanese Adult and Pediatric Patients with Atopic Dermatitis: A Phase III, Long-Term, Open-Label Study
por: Saeki, Hidehisa, et al.
Publicado: (2022)

Indirect Treatment Comparison of Baricitinib versus Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis
por: de Bruin-Weller, Marjolein S., et al.
Publicado: (2022)

Exploratory analyses of biomarkers in blood and stratum corneum in patients with atopic dermatitis
por: Maruyama, Ayano, et al.
Publicado: (2022)

The Eosinophil-to-Lymphocyte Ratio Acts as an Indicator for Improvement of Clinical Signs and Itch by Upadacitinib Treatment in Atopic Dermatitis
por: Hagino, Teppei, et al.
Publicado: (2023)

Impact of the Family and Household Environment on Pediatric Atopic Dermatitis in Japan
por: Saeki, Hidehisa, et al.
Publicado: (2023)

Dermatologist and Patient Perceptions of Treatment Success in Alopecia Areata and Evaluation of Clinical Outcome Assessments in Japan
por: Macey, Jake, et al.
Publicado: (2021)

A phase 3 randomized, multicenter, double-blind study to evaluate the safety of upadacitinib in combination with topical corticosteroids in adolescent and adult patients with moderate-to-severe atopic dermatitis in Japan (Rising Up): An interim 24-week analysis
por: Katoh, Norito, et al.
Publicado: (2021)

Emerging systemic JAK inhibitors in the treatment of atopic dermatitis: a review of abrocitinib, baricitinib, and upadacitinib
por: Nezamololama, Novin, et al.
Publicado: (2020)

Ixekizumab 80 mg Every 2 Weeks Treatment Beyond Week 12 for Japanese Patients with Generalized Pustular Psoriasis and Erythrodermic Psoriasis
por: Morita, Akimichi, et al.
Publicado: (2021)

Effectiveness and Safety of Upadacitinib in Combination with Topical Corticosteroids in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis
por: Hagino, Teppei, et al.
Publicado: (2023)

Baricitinib: The First Jak Inhibitor Approved in Europe for the Treatment of Moderate to Severe Atopic Dermatitis in Adult Patients
por: Radi, Giulia, et al.
Publicado: (2021)

The ability of biomarkers to assess the severity of atopic dermatitis
por: Nakahara, Takeshi, et al.
Publicado: (2023)

Co‐expression of Thymidine Phosphorylase and Heme Oxygenase‐1 in Macrophages in Human Malignant Vertical Growth Melanomas
por: Torisu‐Itakura, Hitoe, et al.
Publicado: (2000)

Relationship Between Rapid Skin Clearance and Quality of Life Benefit: Post Hoc Analysis of Japanese Patients with Moderate-to-Severe Psoriasis Treated with Ixekizumab (UNCOVER-J)
por: Honma, Masaru, et al.
Publicado: (2020)

Tralokinumab Efficacy Over 1 Year in Adults with Moderate-to-Severe Atopic Dermatitis: Pooled Data from Two Phase III Trials
por: Simpson, Eric L., et al.
Publicado: (2023)

Comparative efficacy and safety of abrocitinib, baricitinib, and upadacitinib for moderate‐to‐severe atopic dermatitis: A network meta‐analysis
por: Wan, Huiying, et al.
Publicado: (2022)

Long‐term safety and efficacy of delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with atopic dermatitis
por: Nakagawa, Hidemi, et al.
Publicado: (2019)

Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis: A Randomized Clinical Trial
por: Reich, Kristian, et al.
Publicado: (2020)

Profile of Baricitinib and Its Potential in the Treatment of Moderate to Severe Atopic Dermatitis: A Short Review on the Emerging Clinical Evidence
por: Napolitano, Maddalena, et al.
Publicado: (2020)

Itch and Sleep Improvements with Baricitinib in Patients with Atopic Dermatitis: A Post Hoc Analysis of 3 Phase 3 Studies
por: Buhl, Timo, et al.
Publicado: (2021)

Daily Practice Experience of Baricitinib Treatment for Patients with Difficult-to-Treat Atopic Dermatitis: Results from the BioDay Registry
por: BOESJES, Celeste M., et al.
Publicado: (2022)

The Treat-to-Target Project in Atopic Dermatitis: One Year On
por: DE BRUIN-WELLER, Marjolein, et al.
Publicado: (2023)

T-regulatory cells in severe atopic dermatitis: alterations related to cytokines and other lymphocyte subpopulations
por: Samochocki, Zbigniew, et al.
Publicado: (2012)

Impact of baricitinib in combination with topical steroids on atopic dermatitis symptoms, quality of life and functioning in adult patients with moderate‐to‐severe atopic dermatitis from the BREEZE‐AD7 Phase 3 randomized trial
por: Wollenberg, A., et al.
Publicado: (2021)

Comparison of Treatment Goals between Users of Biological and Non-Biological Therapies for Treatment of Psoriasis in Japan
por: Okubo, Yukari, et al.
Publicado: (2021)

The contribution of itch and skin severity improvements to the Dermatology Life Quality Index in patients with atopic dermatitis in baricitinib phase III trials
por: Yosipovitch, Gil, et al.
Publicado: (2022)

Effectiveness of Upadacitinib in Patients with Atopic Dermatitis including those with Inadequate Response to Dupilumab and/or Baricitinib: Results from the BioDay Registry
por: BOESJES, Celeste M., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_809l248t55m8ssol05nbjl2era